GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reunion Neuroscience Inc (TSX:REUN) » Definitions » Capex-to-Operating-Income

Reunion Neuroscience (TSX:REUN) Capex-to-Operating-Income : 0.00 (As of Mar. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Reunion Neuroscience Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Reunion Neuroscience's Capital Expenditure for the three months ended in Mar. 2023 was C$0.00 Mil. Its Operating Income for the three months ended in Mar. 2023 was C$-6.85 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Reunion Neuroscience Capex-to-Operating-Income Historical Data

The historical data trend for Reunion Neuroscience's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reunion Neuroscience Capex-to-Operating-Income Chart

Reunion Neuroscience Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Capex-to-Operating-Income
- - - -

Reunion Neuroscience Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Reunion Neuroscience's Capex-to-Operating-Income

For the Biotechnology subindustry, Reunion Neuroscience's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reunion Neuroscience's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reunion Neuroscience's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Reunion Neuroscience's Capex-to-Operating-Income falls into.



Reunion Neuroscience Capex-to-Operating-Income Calculation

Reunion Neuroscience's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.246) / -27.963
=N/A

Reunion Neuroscience's Capex-to-Operating-Income for the quarter that ended in Mar. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -6.854
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reunion Neuroscience  (TSX:REUN) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Reunion Neuroscience Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Reunion Neuroscience's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Reunion Neuroscience (TSX:REUN) Business Description

Traded in Other Exchanges
N/A
Address
30 Duncan Street, Lower North Suite, Toronto, ON, CAN, M5V 2C3
Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.